ConductScience.org, home

Paper42459699

Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.

Wang T and 2 others. Front Immunol, 2026. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy. Papers, record 42459699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42459699

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.
PubMed
Journal
Front Immunol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2026-08-13
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wang TTong
2Xu WWenlong
3Wu XXiaofeng

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Neoadjuvant TherapyMajor topic
Tertiary Lymphoid StructuresMajor topic
ImmunotherapyMajor topic
NeoplasmsMajor topic
Biomarkers, TumorMajor topic
Humans
Tumor Microenvironment
Animals
Immune Checkpoint Inhibitors

Source PubMed

Download CSV of topics

References71

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138114518Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.Nat Commun2023https://conductscience.org/library/papers/38114518PubMed
229279354Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.Cancer Res2018https://conductscience.org/library/papers/29279354PubMed
336056951
The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Cancer Immunol Immunother2023https://conductscience.org/library/papers/36056951PubMed
435403841Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.N Engl J Med2022https://conductscience.org/library/papers/35403841PubMed
538012408Decoding the tumor microenvironment with spatial technologies.Nat Immunol2023https://conductscience.org/library/papers/38012408PubMed
638057283
Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Thorac Cancer2024https://conductscience.org/library/papers/38057283PubMed
728899864Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.Cancer Discov2017https://conductscience.org/library/papers/28899864PubMed
837055640Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA.Nature2023https://conductscience.org/library/papers/37055640PubMed
941972153Clinicopathological and molecular characteristics associated with pathological complete response in neoadjuvant immunotherapy for breast cancer.Front Immunol2026https://conductscience.org/library/papers/41972153PubMed
1039314905Immune priming and induction of tertiary lymphoid structures in a cord-blood humanized mouse model of gastrointestinal stromal tumor.Oncoimmunology2024https://conductscience.org/library/papers/39314905PubMed
1131092904Tertiary lymphoid structures in the era of cancer immunotherapy.Nat Rev Cancer2019https://conductscience.org/library/papers/31092904PubMed
1233277370Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.Clin Cancer Res2021https://conductscience.org/library/papers/33277370PubMed
1338066335How chemokines organize the tumour microenvironment.Nat Rev Cancer2024https://conductscience.org/library/papers/38066335PubMed
1438458196An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure.Cell Rep Med2024https://conductscience.org/library/papers/38458196PubMed
1538340557Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer.EBioMedicine2024https://conductscience.org/library/papers/38340557PubMed
1635969830
Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.
J Clin Oncol2023https://conductscience.org/library/papers/35969830PubMed
1736795255Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.Ann Surg Oncol2023https://conductscience.org/library/papers/36795255PubMed
1831942075B cells and tertiary lymphoid structures promote immunotherapy response.Nature2020https://conductscience.org/library/papers/31942075PubMed
1937870974Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.N Engl J Med2023https://conductscience.org/library/papers/37870974PubMed
2032001626Neoadjuvant checkpoint blockade for cancer immunotherapy.Science2020https://conductscience.org/library/papers/32001626PubMed

See all 71 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42787593Tertiary lymphoid structures in neoadjuvant and perioperative cancer immunotherapy: a review and proposed framework for biomarker interpretation and validation.Front Immunol2026https://conductscience.org/library/papers/42787593PubMed
42724854Combined multi-omics profiling and machine learning analysis reveals that Bregs and RPS2 promote bone metastasis in nasopharyngeal carcinoma.Transl Cancer Res2026https://conductscience.org/library/papers/42724854PubMed
42598915TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC.Thorac Cancer2026https://conductscience.org/library/papers/42598915PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42459699

GET https://conductscience.org/api/papers/v1/42459699/references?page=2